Cypher select stent
WebCordis Corporation recently announced that it has received CE mark approval for the treatment of acute myocardial infarction (AMI) using the CYPHER® SELECT™ PLUS … WebApr 19, 2010 · The NEVO™ Sirolimus-eluting Coronary Stent is a cobalt-chromium alloy stent platform that incorporates two unique features: reservoir technology, and a …
Cypher select stent
Did you know?
WebERodable Stent coating (LEADERS) multicenter noninferiority trial randomized 1707 p atients to either the BioMatrix Flex or Cypher Select ® stent (Cordis Corp., FL, USA) [20]. The BioMatrix Flex stent was found to be noninferior to the Cypher Select for the composite primary end point of cardiac death, myocardial infarction WebThe company will also stop the manufacture of CYPHER ® and CYPHER SELECT ® Plus Sirolimus-Eluting Coronary Stents by the end of 2011. “Due to evolving market dynamics in the drug-eluting stent (DES) business, we see greater opportunities to benefit patients and grow our business in other areas of the cardiovascular device market,” said ...
WebDec 1, 2011 · Stent deliverability, strongly influenced by flexibility, is the property that cardiologists desire most (1, 10), and designs that have high longitudinal integrity may not have high flexibility and deliverability. We show that the earlier generation Cypher Select, a 6-connector design, had the greatest resistance to longitudinal distorting forces. Webflexible stent platform for improved deliverability. The most recent three-year data shows a strong trend towards a significantly lower rate of MACE (Major Adverse Cardiac Events) in patients treated with BioMatrix Flex versus those treated with Cypher® Select™, in an “all comers” patient population.6 Occurrence of late stent
WebJun 1, 2010 · Noninferiority was confirmed for the BioMatrix Flex stent compared with Cypher Select from the largest pool of evidence comparing a bioabsorbable and a durable polymer stent. Furthermore the 2 ... WebHome - MagResource
WebThe sirolimus-eluting stent (CYPHER( trade mark )) is a metal stent coated with 140 micro g/cm(2) of sirolimus blended with synthetic polymers. After stent implantation, sirolimus is slowly released causing localized cytostatic inhibition of proliferation of vascular smooth muscle cells in the peri-stent arterial wall over a period of about 1 ...
WebPatients were randomly assigned in a 1:1:1 ratio to receive a first-generation sirolimus-eluting stent (Cypher Select, Cordis), a bare-metal (cobalt–chromium) stent (Vision, Abbott Vascular), or ... how to stop wheezing immediatelyWebLow Late Loss. Lower level of late loss achieved in the LEADERS trial with the BioMatrix Flex™ (Biolimus A9™) eluting stent at 9 months compared to the Cypher® Select™ stent 6; In Stent late loss in LEADERS = 0.13mm 6; Highest lipophilicity of the common limus drugs 1. Minimizes systemic exposure and reduces the drug circulating in the bloodstream how to stop wheezing at night naturallyWebJun 15, 2011 · Cordis Announces Plans to Discontinue Cypher Stents, Drop Nevo Development By L.A. McKeown In a surprise move, Cordis Corporation will stop making … how to stop wheezing when lying downWebOct 18, 2006 · Detailed Description: Compare the safety and efficacy of the BioMatrix Flex (Biolimus A9-Eluting) stent system with the Cypher SELECT (Sirolimus-Eluting) stent system in a prospective, multi-center, randomized, controlled, non-inferiority trial in patients undergoing percutaneous coronary intervention in routine clinical practice. how to stop wheezing lungsWebApr 25, 2008 · Angiographic follow-up at 9 months was performed in 418 (68.3%) lesions treated by CYPHER Select SES. The binary restenosis rate was 4.8% in-stent and 9.6% … how to stop wheezing from asthmaWebPurpose: Therefore, we investigated late in-stent stenosis, thrombogenicity, and inflammation, comparing the CYPHER-Select, TAXUS-Express, and custom-made … read sonia parin online freeWebOct 5, 2005 · A total of 100 patients will be entered in the study and will be randomized on a 2:1 basis to the CYPHER SELECT™ stent or the CYPHER™ stent. 100 patients with de novo native coronary artery lesions <23 mm in length and more than 2.5 to less than 3.5 mm in diameter by visual estimate who meet all eligibility criteria will be either randomized. read soft file in r